Mechanistic Modeling of Soluble A β Dynamics and Target Engagement in the Brain by Anti-Aβ mAbs in Alzheimer's Disease.

CONCLUSION: This model is useful for comparing target engagement profiles of different anti-Aβ therapies and demonstrates that 60 mg/kg crenezumab yields a significant increase in Aβ engagement compared with lower doses of solanezumab, supporting the selection of 60 mg/kg crenezumab for phase 3 studies. The model also provides evidence that delivery of sufficient quantities of mAb to brain interstitial fluid is a limiting step with respect to the magnitude of soluble Aβ oligomer neutralization.
PMID: 32116192 [PubMed - as supplied by publisher]

Source: Current Alzheimer Research - March 1, 2020 Category: Neurology Authors: Ferl GZ, Fuji RN, Atwal JK, Sun T, Ramanujan S, Quartino AL Tags: Curr Alzheimer Res Source Type: research